Evotec Stock - weekly review and sector comparison
19.06.2026 - 21:18:07 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 21:16 CET. Details in the imprint.
Evotec (DE0005664809) has seen a muted trading week on Xetra as investors continue to reassess European biotech risk. With no new company-specific headlines from its investor relations page, the stock has largely tracked sector moves and broader risk appetite.
Background and data on Evotec stock
Key news, estimates and price data on Evotec are bundled in the ad-hoc-news topic area and on the company’s own investor relations pages.
How Evotec traded this week
On Xetra, Evotec shares recently changed hands at around EUR 4.54, leaving the stock down roughly 4% on the day and extending a generally soft tone in June trading. MarketScreener quote data show intraday levels fluctuating in a relatively narrow band.
The company’s Nasdaq-listed American depositary shares, which trade under the ticker EVO, closed at $2.57 on 06/18/2026, according to recent quote information, reflecting the lower absolute price level after past volatility. MarketBeat’s overview highlights the ADR as a smaller, more thinly traded line compared with the German listing.
Position in the biotech peer group
Evotec operates in the European biotech and drug discovery services space, a segment that has experienced sustained pressure amid higher interest rates and selective risk-taking. In that context, the company’s market value in the mid-hundreds of millions of euros places it below some larger integrated peers.
Against this backdrop, Evotec’s recent share performance broadly mirrors the cautious sentiment in European life sciences rather than any clear company-specific trend. Trading volumes have not indicated outsized conviction one way or the other, suggesting a wait-and-see stance among many investors.
The product and service engine
Evotec generates revenue primarily by providing integrated drug discovery and development services, including high-throughput screening, medicinal chemistry and preclinical testing for pharmaceutical and biotech clients. The company also pursues partnered R&D projects that can yield milestone and royalty streams when candidates advance.
Where the stock trades today
The shares of Evotec (DE0005664809) trade on Xetra at EUR 4.54 as of 06/19/2026, 17:35 CET.
Key facts on Evotec stock
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVT
- Venue: Xetra
- Price (as of 06/19/2026, 17:35 CET): 4.54 EUR
- Market cap: 804,000,000 EUR (as of 06/19/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: TecDAX
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
